BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We had another strong quarter of execution for both navenibart and STAR-0310,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We are excited about the opportunity for navenibar.
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024. Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and.
Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, President & Director Noah Clauser - CFO & Treasurer Christopher Morabito - Chief Medical Officer Andrea Matthews - Chief Business Officer Andrew Komjathy - Chief Commercial Officer Conference Call Participants Eun Yang - Jefferies Sam Slutsky - LifeSci Capital Hartaj Singh - Oppenheimer Farhana Sakloth - Ladenburg Joe Pantginis - H.C. Wainwright Operator Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update.
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the Unive.
Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases. The focus of the collaboration centers on the development of the lead candidate, STAR-0310, a monoclonal antibody OX40 antagonist utilizing YTE half-life extension technology.
Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.
Astria: Biotech To Watch With Proof Of Concept Established For HAE.